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ABSTRACT
Women receiving neoadjuvant systemic therapy 
for primary operable or inoperable breast cancer 
can potentially benefit in a number of ways, but the 
main advantage, which has been consistently demon-
strated, is improved tumour resectability. Given the 
improvement in outcomes with the adjuvant use of 
trastuzumab in patients with early-stage breast can-
cer positive for the human epidermal growth factor 
receptor 2 (her2), questions have been raised about 
the use of trastuzumab in the neoadjuvant setting. 
The present paper reviews the currently available data 
and outlines suggestions from a panel of Canadian 
oncologists about the use of trastuzumab and other 
her2-targeted agents in the neoadjuvant setting.
The panel focussed on
•  the use of trastuzumab and other her2-targeted 
agents as neoadjuvant therapy in primary oper-
able, locally advanced, and inflammatory breast 
cancer; and
•  possible choices of chemotherapeutic regimens 
with trastuzumab.
The suggestions described here will continue to 
evolve as data from current and future trials with tras-
tuzumab and other her2-targeted agents emerge.
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1.  INTRODUCTION
Chemotherapy produces similar survival gains 
whether given in the neoadjuvant or the adjuvant set-
ting. A meta-analysis of randomized trials comparing 
neoadjuvant with adjuvant chemotherapy found no 
difference in distant disease recurrence [risk ratio 
(rr): 0.94; 95% confidence interval (ci): 0.83 to 1.06] 
or overall survival rate (rr: 1.00; 95% ci: 0.90 to 
1.12) 1. Notably, however, most of the patients in the 
relevant trials had operable cancer at randomization.
In the clinical setting, neoadjuvant therapy has 
several potential advantages over standard adjuvant 
therapy. First, for operable tumours, the use of neoad-
juvant therapy increases the rate of breast-conserving 
surgery 2,3, with the caveat that neoadjuvant therapy 
is associated with an increase in locoregional recur-
rence (rr: 1.22; 95% ci: 1.04 to 1.43), especially in 
younger women (in whom tamoxifen was not given 
at the time that the trial was conducted) and in women 
for whom a mastectomy was initially proposed but 
was changed to breast-conserving surgery after 
neoadjuvant chemotherapy 2. Second, given that a 
pathologic complete response (pcr) is a surrogate 
marker for improved clinical outcome 2, neoadjuvant 
therapy provides an opportunity to undertake cor-
relative research by allowing in vivo assessment of 
tumour response to particular drug regimens 3. Lastly, 
from a practical viewpoint, neoadjuvant therapy al-
lows patients to start treatment earlier if surgical wait 
times are too long. Neoadjuvant therapy also has its 
disadvantages, however. First, there is about a 5% 
chance that tumour progression may occur during 
neoadjuvant treatment, thereby delaying definitive 
local therapy 4. In addition, neoadjuvant treatment 
prevents definitive pathologic staging.
Locally advanced breast cancer (labc) and inflam-
matory breast cancer (ibc) are, by definition, inoper-
able, and neoadjuvant therapy is therefore the sole 
treatment option. Chia et al. 5 and Anderson et al. 6 
both described labc as stage iii disease (excluding T4d 
tumours), with a heterogeneous clinical phenotype 49
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that ranges from neglected low-grade estrogen recep-
tor (er)–positive to rapidly progressing er-negative 
breast cancer. On the other hand, ibc (T4d) appears to 
have a different epidemiology, is typically diagnosed 
at a younger age, and is generally associated with 
higher tumour grade, negative er status, and increased 
angiogenesis and lymphangiogenesis; historically, ibc 
has a worse survival rate 5–8.
The human epidermal growth factor receptor 2 
(her2) is a transmembrane tyrosine kinase receptor 
protein that is part of the her family of growth factor 
receptors (her1–her4). The her2 receptor is involved 
in cell–cell and cell–stroma communication primar-
ily through signal transduction involving the Ras/
mitogen-activated protein kinase pathway and the 
phosphoinositide 3 kinase (pi3k)/Akt pathway 9. These 
signals ultimately promote cell proliferation, survival, 
and motility. Amplification of the her2/neu gene and 
resulting overexpression of the her2 protein occurs in 
approximately 15%–20% of invasive primary breast 
cancers 10,11. Compared with her2-negative cancers, 
early-stage breast cancer with a her2 alteration is as-
sociated with more aggressive disease and a higher 
risk of relapse 12–16.
Trastuzumab is a monoclonal antibody that 
binds to the extracellular domain of her2. Several 
mechanisms of action underlie the antitumour ef-
fects of trastuzumab. Trastuzumab blocks her2-
activated cell signalling, thereby reducing cell 
proliferation and restoring a capacity for apoptosis 
by inhibiting the  pi3k/Akt pathway 17–19, which 
increases cellular sensitivity to chemotherapy and 
radiotherapy 20. Trastuzumab has been shown to 
inhibit her2-regulated angiogenesis 17,21–23 and, in 
preclinical models, to recruit the immune system 
through antibody-dependent cellular cytotoxicity, 
triggering activation of natural killer cell–mediated 
apoptosis 24–26. Trastuzumab has also been shown 
to prevent the formation of p95
her2 (a truncated, ac-
tive form of her2), which may lead to inhibition of 
tumour development 17,27.
Trastuzumab is now the standard of care in 
the adjuvant setting. A meta-analysis 28 of the five 
randomized controlled trials in the adjuvant setting 
[North Central Cancer Treatment Group (ncctg) 
9831, National Surgical Adjuvant Breast and Bowel 
Project (nsabp) B31, the Herceptina Adjuvant (hera) 
trial, the Finland Herceptin (FinHer) trial, and Breast 
Cancer International Research Group 006] 29–32 
comparing chemotherapy plus trastuzumab with che-
motherapy alone in her2-positive disease observed a 
relative reduction in relapse of 47% (absolute reduc-
tion: 7.1%) and a relative reduction in mortality rate 
of 48% (absolute reduction: 2.5%) after a follow-up 
of 2–3 years.
The body of studies evaluating the use of her2-
targeted agents in neoadjuvant therapy for both 
a  Trademark of Genentech, San Francisco, CA, U.S.A.
primary operable and primary inoperable  her2-
positive breast cancer is growing, and the present 
paper reviews the current evidence and outlines 
suggestions from a panel of Canadian oncologists 
about the neoadjuvant use of trastuzumab and other 
her2-targeted agents.
2.  DEVELOPMENT OF PANEL SUGGESTIONS
The authors of this paper met in Toronto for a 1-day 
conference in June 2008. The panel reviewed the 
results of the latest trials using trastuzumab and other 
her2-targeted agents in the neoadjuvant, adjuvant, 
and metastatic disease settings. Based on trial infor-
mation, suggestions for each setting were formulated. 
For neoadjuvant therapy, a draft manuscript review-
ing the currently available data and outlining the 
suggestions from the panel was initially written by 
a medical writer (BW) and reviewed and revised by 
four panel members (JLe, MC, LP, SC). The final 
manuscript was reviewed and approved by the rest 
of the panel members (SD, JLa, JM, KIP, DR, ShV, 
SuV). Recent clinical trial results (available as of June 
2009) were incorporated into the present document, 
and the conclusions discussed were updated as ad-
ditional evidence became available.
Development of the Canadian advisory panel and 
the present manuscript were funded by an unrestricted 
educational grant from Hoffmann–La Roche Canada. 
The authors received an honorarium for attending the 
conference, but not for writing the manuscript. The 
authors are responsible for the content of the manu-
script, with no restrictions set by the sponsor.
The panel focussed on
•  the use of trastuzumab and other her2-targeted 
agents as neoadjuvant therapy in primary oper-
able, locally advanced, and inflammatory breast 
cancer; and
•  possible choices of chemotherapeutic regimens 
with trastuzumab.
The related clinical evidence is presented and 
discussed below. Key panel suggestions are followed 
by a discussion of the supporting evidence, the panel’s 
rationale for the suggestions, and any points on which 
consensus was lacking.
3.  NEOADJUVANT TRIALS USING 
TRASTUZUMAB
Two recently reported randomized controlled pro-
spective trials comparing chemotherapy with and 
without her2-targeted therapy in the neoadjuvant 
setting (Table i) are reviewed here.
3.1  MD Anderson Trial
In a small, two-arm, phase iii randomized prospective 
trial, Buzdar et al. compared 225 mg/m2 paclitaxel 50
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in a 24-hour continuous intravenous infusion every 
3 weeks for 4 cycles, followed by fec [500 mg/
m2 5-fluorouracil (5fu) on days 1 and 4, 75 mg/m2 
epirubicin on day 1, 500 mg/m2 cyclophosphamide 
on day 1] every 3 weeks for 4 cycles as neoadjuvant 
therapy without (p→fec) and with [h+(p→fec)] con-
current trastuzumab (4 mg/kg loading dose on day 1 
of the first treatment cycle before paclitaxel, and 
2 mg/kg maintenance dose weekly for 24 doses) 3. 
The study accrued 42 patients with histologically 
confirmed invasive, but noninflammatory, stage ii–
iiia carcinoma of the breast. The primary objective 
was to demonstrate a doubled improvement in pcr—
defined as no evidence of residual invasive cancer 
in both breast and axilla—with the addition of tras-
tuzumab to chemotherapy. The trastuzumab-based 
treatment arm displayed a pcr improvement by a 
factor of 2.5 relative to chemotherapy alone (65.2% 
vs. 26.3%, p = 0.016). As a result of the superior 
response attributed to trastuzumab, the data analysis 
was presented to the MD Anderson Data Monitor-
ing Committee. Based on recommendations by that 
committee, the protocol of the original study was 
changed to discontinue the chemotherapy-alone arm. 
Recruitment was continued in the h+(p→fec) arm 
only. A total of 45 patients received the h+(p→fec) 
regimen. The pcr rate for the updated combined tras-
tuzumab treatment arm (n = 45) was also superior to 
chemotherapy alone (60% vs. 26.3%; 95% ci: 44.3% 
to 74.3%; Table i) 33. Notably, trastuzumab was given 
concomitantly with epirubicin. The median left ven-
tricular ejection fraction (lvef) was 65% at baseline 
in the both trial arms; after 6 months, the median lvef 
was 65% (range: 55%–70%) in the (p→fec) arm, but 
60% (range: 52%–70%) in the h+(p→fec) arm. No 
clinical cardiac dysfunction was reported; however, 
the sample size was small, and the follow-up dura-
tion was short.
3.2  Neoadjuvant Herceptin Trial
The international multicentre phase iii randomized 
noah (Neoadjuvant Herceptin) trial compared the 
efficacy of doxorubicin (60 mg/m2) and paclitaxel 
(150 mg/m2) every 3 weeks for 3 cycles, followed 
by paclitaxel alone (175 mg/m2) every 3 weeks for 
4 cycles, followed by cyclophosphamide (600 mg/
m2), methotrexate (40 mg/m2), and 5fu (600 mg/m2) 
every 4 weeks on days 1 and 8 for 4 cycles without 
(ap→p→cmf) and with [h+(ap→p→cmf)] concur-
rent trastuzumab [8 mg/kg loading dose, then 6 mg/
kg every 3 weeks (concurrent with cycle 1 onward) 
continued to 52 weeks] as first-line therapy in patients 
with her2-overexpressing labc (including ibc) 34. A 
her2-negative third arm was also accrued as reference 
for the her2-overexpressing arms, but these patients 
were not given trastuzumab. Data presented here refer 
to the group of her2-positive patients (trastuzumab 
arm vs. no trastuzumab arm).
The primary endpoint was event-free survival 
(efs), which was defined as progression on therapy, 
relapse after surgery, or death from any cause. The 
secondary endpoints were pcr rate, overall survival, 
and safety and tolerability. In both her2-positive 
arms (with and without trastuzumab), 42%–43% 
of the patients presented with T4 noninflammatory 
breast cancer, 27% presented with ibc, and 30%–31% 
presented with N2 disease. In the intention-to-treat 
population (n = 227), patients receiving trastuzumab 
(n = 115) experienced a significantly improved 3-year 
efs rate relative to chemotherapy alone [70.1% vs. 
53.3%; hazard ratio (hr): 0.56; 95% ci: 0.36 to 0.85; 
p = 0.006; Table i].
In addition, the pcr rate was significantly higher 
in the trastuzumab-containing treatment arm (43% 
vs. 23%, p = 0.002), and a trend toward improved 
overall survival was observed (hr: 0.65; 95% ci: 0.34 
to 1.23; p = 0.18) 34. The rate of breast-conserving 
surgery nearly doubled in the trastuzumab arm (23% 
vs. 12.5%, p = 0.07) 36. In the subgroup of patients 
with her2-positive ibc (n = 61), the addition of tras-
tuzumab to chemotherapy also significantly improved 
pcr (55% vs. 19%, p = 0.004) and total pcr (48% vs. 
13%, p = 0.002) 35.
Neoadjuvant trastuzumab was well tolerated with 
reasonable cardiac safety. Only a 2.1% cumulative 
incidence of New York Heart Association (nyha) 
grade 3 congestive heart failure (chf) was observed 
in the trastuzumab arm 34 even though trastuzumab 
was delivered concurrently with doxorubicin (60 mg/
m2) and paclitaxel (150 mg/m2). In contrast, the 
non-trastuzumab-containing group in her2-positive 
patients and the her2-negative group both reported 
no incidence of nyha grade 3 chf.
Although this study is very interesting, to date it 
has been published only in abstract form. No other 
randomized trials have compared trastuzumab with no 
trastuzumab treatment. However, a number of other 
ongoing trials have included trastuzumab as part of the 
treatment arm in the her2-overexpressing cohort.
The two trials presented next included concomi-
tant (GeparQuattro) or sequential (techno) anthracy-
clines and trastuzumab. 
3.3  GeparQuattro Trial
A multicentre prospective randomized three-arm trial 
studied the possible benefits of adding capecitabine, 
either concomitantly or sequentially, to docetaxel 
after 4 cycles of epirubicin (90 mg/m2) and cyclo-
phosphamide (600 mg/m2) 37 (ec). Patients with 
her2-positive breast cancer received trastuzumab 
for 1 year, starting with ec in all three arms, thereby 
collecting data on the cardiac safety of trastuzumab 
and anthracyclines given concomitantly. Results 
presented in an abstract form showed only that neo-
adjuvant trastuzumab was well tolerated, with no 
cases of grade 4 congestive heart failure. No patients 52
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showed a decrease in lvef to below 45%. The pcr 
rate in a combined analysis of all three her2-positive 
treatment arms treated with concurrent trastuzumab 
was 45%. Investigators concluded that the addition 
of trastuzumab to chemotherapy was feasible without 
clinically relevant cardiotoxicity.
3.4  Taxol Epirubicin Cyclophosphamide Herceptin 
Neoadjuvant Trial
The multicentre phase ii single-arm Taxol Epirubicin 
Cyclophosphamide Herceptin Neoadjuvant (techno) 
trial (NCT00795899) examined the safety and effica-
cy of epirubicin (90 mg/m2) and cyclophosphamide 
(600 mg/m2) every 3 weeks for 4 cycles, followed 
by trastuzumab (8 mg/kg loading dose, followed by 
6 mg/kg) and paclitaxel (175 mg/m2) every 3 weeks 
for 4 cycles as neoadjuvant therapy in patients 
with her2-positive primary breast cancer >2 cm 
or inflammatory disease 38. After surgery, patients 
continued trastuzumab (6 mg/kg) every 3 weeks 
for 12 cycles. The primary clinical endpoints were 
histopathologic response rates (breast and axilla) and 
overall cardiac toxicity; secondary endpoints were 
disease-free survival, overall survival, rate of breast 
conservation, and quality of life. This trial has been 
completed. In an abstract presented in 2006, the pcr 
rate was 20% 39.
4.  NEOADJUVANT TRIALS USING LAPATINIB
Recently, Migliaccio et al. 19 performed two sequen-
tial single-arm neoadjuvant clinical trials in her2-
overexpresing labc patients to compare the clinical 
efficacy and mechanism of action of trastuzumab 
with those of lapatinib, an oral epidermal growth 
factor receptor/her2 tyrosine kinase inhibitor. Pa-
tients in the single-arm trastuzumab trial were given 
a standard trastuzumab dose for the first 3 weeks 
followed by trastuzumab and standard docetaxel 
every 3 weeks for 12 weeks (n = 35). Patients in the 
lapatinib single-arm trial were given 1500 mg oral 
lapatinib daily for 6 weeks followed by trastuzumab 
and standard docetaxel every 3 weeks for 12 weeks 
(n = 49). Clinical efficacy of the trial that gave initial 
trastuzumab, as determined by the pcr rate [defined 
here as the complete disappearance of all invasive 
cancer or minute foci of residual disease (<0.5 cm) 
in breast], was 34% (11/32) as compared with 68% 
(23/34) in the trial that gave initial lapatinib. It must be 
noted that, because both trials used trastuzumab with 
docetaxel, the lapatinib trial was not a lapatinib-only 
design. Further study results showed that tumours 
with low pten predicted resistance to trastuzumab.
5.  FUTURE STUDIES
Using www.clinicaltrials.gov, we found 14 random-
ized clinical trials for her2-positive breast cancer in 
the neoadjuvant setting (Table ii). Most of these trials 
used pcr as the primary endpoint.
Eight trials compared trastuzumab with lapatinib 
or a combination of both agents. One trial (NeoSphere) 
is currently examining the safety and efficacy of the 
various combinations of trastuzumab and pertuzumab, 
another monoclonal antibody that targets her2, in the 
presence or absence of chemotherapy for labc or ibc. 
As a complement to trastuzumab, pertuzumab inhibits 
the her2-mediated signalling pathway by binding to 
a different epitope on the her2 extracellular domain, 
thereby preventing  her2 dimerization with other 
members of the her2 family 40. In vitro evidence 
suggests that these two agents act synergistically to 
inhibit the survival of breast cancer cells 41, suggest-
ing that the combination of these two agents would 
be a more effective therapeutic strategy.
The American College of Surgeons Oncology 
Group (acosog) Z1041 trial is examining the se-
quence of fec75–paclitaxel plus trastuzumab, in which 
fec75 is given either before or after the paclitaxel and 
trastuzumab. Other trials are testing new agents such 
as everolimus.
The German Breast Group 44 trial (GeparQu-
into) will randomize 2547 patients to six arms: 
one without neoadjuvant targeted therapy, one 
with bevacizumab, one with only trastuzumab and 
no chemotherapy, one with everolimus, one with 
chemotherapy plus trastuzumab, and one with che-
motherapy plus lapatinib. These large clinical trials 
may answer many clinical questions, such as “Is it 
better to give a combination of targeted agents rather 
than one agent?”
6.  PANEL SUGGESTIONS FOR TREATMENT 
IN NEOADJUVANT THERAPY
6.1  HER2-Targeted Agents as Neoadjuvant Therapy 
in HER2-Positive Primary Operable LABC or IBC
Suggestion: Currently, the panel felt that trastu-
zumab is standard in the neoadjuvant setting in 
combination with chemotherapy in patients with 
her2-overexpressing breast cancer when a clinical 
decision has been made to treat with neoadjuvant 
chemotherapy. Other her2-targeting agents such as 
lapatinib and pertuzumab should be given only as 
part of a clinical trial.
Discussion: The addition of trastuzumab in neo-
adjuvant systemic therapy clearly increases pcr in 
primary operable breast cancer, and a growing body 
of clinical evidence shows a similar result in labc 
and ibc3,33–35,37. Furthermore, increased pcr after 
preoperative therapy has been shown to be a surro-
gate marker for long-term disease-free survival and 
overall survival in some trials 2,3. However, in the 
nsabp B27 trial, despite increased pcr, no survival 
advantage was shown with the addition of docetaxel 53
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table ii  Future studies with her2–targeted therapy in the neoadjuvant setting
Trial name Type Treatment Expected Estimated
(ClinicalTrials.gov id) accrual completion date
acosog-Z1041(NCT00513292) Phase iii fec75→th 270 June 2008
vs. th→fec75 + h
EGF106988 (NCT00429299) Phase ii Chemotherapy + l 120 June 2009
vs. chemotherapy + h
vs. chemotherapy + lh
03–311 (NCT00148668) Phase ii h + vinorelbine 81 December 2009
vs. dcbh
Neo altto (NCT00553358) Phase iii lh→lht 450 April 2010
vs. l→lt
vs. h→ht
calgb-40601 Phase iii h + t + l 400 June 2010
(NCT00770809) vs. h + t
vs. t + l
nsabp B-41 (NCT00486668) Phase iii ac→th 522 July 2010
vs. ac→tl
vs. ac→thl
GSK-LAP107087 (NCT00499681) Phase ii l + letrozole 36 July 2010
vs. placebo + letrozole
1200.44 (NCT00826267) Phase ii bibw 2992 120 December 2010
vs. l
vs. h
gbg 44 (NCT00567554) Phase iii ec→d 2547 December 2010
vs. ec→d + b
vs. t
vs. t + everolimus
vs. ec→dh
vs. ec→dl
geicam/2006-14 (NCT00841828) Phase ii ec→d + l 102 December 2011
vs. ec→d + h
EU-20851 (NCT00674414) Phase ii h 120 April 2014
vs. h + everolimus
NeoSphere (NCT00545688) Phase ii h + d 400 August 2014
vs. h + p + d
vs. h + p
vs. p + d
H-20464 (NCT00548184) Phase ii hl 64 January 2015
vs. hl + endocrine therapy
LPT109096 (NCT00524303) Phase ii fec75→th 99 Not available
vs. fec75→thl
f = 5-fluorouracil; e = epirubicin; c = cyclophosphamide; t = paclitaxel; h = trastuzumab; l = lapatinib; d = docetaxel; cb = carboplatin; 
a = doxorubicin; b = bevacizumab; p = pertuzumab.
to an anthracycline-based regimen. Investigation of 
new agents in combination with conventional sys-
temic therapies in the preoperative or neoadjuvant 
setting can provide tissue sampling to assess markers 
of in  vivo tumour responses. As well, pcr can be used 
as a surrogate, allowing for testing of new interven-
tions in smaller phase ii trials before they are studied 
in larger phase iii clinical trials, which require a larger 
sample size and longer follow-up.
The latest and strongest evidence relies on the 
final study results of the noah trial. Here, the addition 
of trastuzumab to chemotherapy in her2-positive 
patients significantly improved event-free survival 
at 3 years relative to chemotherapy alone (70.1% vs. 54
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53.3%; hr: 0.56; 95% ci: 0.36 to 0.85; p = 0.006), 
with an overall survival trend (hr: 0.65; 95% ci: 0.34 
to 1.23; p = 0.18) 34. The hr and absolute benefit for 
the addition of trastuzumab are in the range seen 
during the large adjuvant trials with trastuzumab; 
however, these results were delivered with a much 
smaller number of patients (n = 227 vs. n > 13,000). 
The acceptable cardiac safety data also show that it 
may be reasonable to use a low cumulative dose of 
anthracycline concurrently with trastuzumab. Alto-
gether, the noah trial has demonstrated that neoad-
juvant trastuzumab for 1 year in combination with 
chemotherapy is a standard of care for women with 
labc or ibc her2-positive breast cancer. Publication 
of final results is eagerly awaited.
No trial has tested, or is testing, the effect of 
starting trastuzumab in the neoadjuvant setting 
against starting it after surgery. The  ncctg 9831 
trial has examined the benefits of trastuzumab 
concurrent with chemotherapy versus trastuzumab 
sequential after chemotherapy. Results of the data 
analysis are pending. In regard to duration, based on 
the adjuvant trials, total duration is 1 year at pres-
ent. Studies to determine if a 6-month treatment is 
equivalent to a 12-month treatment (NCT00712140, 
NCT00615602) or if 2 years’ treatment provides 
further benefits over 1 year’s treatment (hera) 
are ongoing. In Finland, a trial is also comparing 
9 weeks with 51 weeks of adjuvant trastuzumab 
(NCT00593697).
6.2  Possible Combination Regimens with Trastuzumab
Suggestion: Currently, the panel felt that concur-
rent trastuzumab with the taxane component of 
commonly-used neoadjuvant regimens is a reasonable 
standard in primary operable, locally advanced, or 
inflammatory breast cancer. However, current data 
are not strong enough to support the concurrent use of 
trastuzumab with anthracyclines, given the potential 
cardiac toxicity.
Discussion: The panel noted that no randomized trials 
were available in labc or ibc to support any particu-
lar trastuzumab-based regimen. Several published 
regimens included concurrent anthracyclines with 
trastuzumab 3,33,34,36, but caution is needed in using 
this approach because the overall sample size in these 
studies is small, the patient populations were highly 
selected, and the primary aim was not the cardiac 
safety of trastuzumab treatment given concurrently 
with anthracyclines. Also, the follow-up for cardio-
toxicity was only short-term. It must be noted that 
the total dose of anthracyclines was lower than that 
usually given in the adjuvant setting, and the risk–
benefit ratio of these regimens is not fully defined. 
Long-term follow-up and randomized comparisons 
of the regimens will be required for definitive recom-
mendations. In the hera trial, higher cumulative doses 
of anthracyclines were found to contribute as a risk 
factor for trastuzumab-associated cardiotoxicity 42. 
Although the population benefiting from anthracy-
clines is that with TOPO2A gene alterations, found 
mainly in her2-positive breast cancers 43, no evidence 
supports concurrent anthracycline and trastuzumab 
in the adjuvant setting. In the metastatic setting, 
anthracyclines given concurrently have been shown 
to be associated with an unacceptable rate of cardiac 
toxicity, and therefore the combination is contrain-
dicated in that setting 44.
In the context of primary operable breast cancer, 
in which patients seek a better chance for breast 
conservation, the panel agreed that all adjuvant data 
could be extrapolated to neoadjuvant therapy for 
clinical benefit, but with a higher chance of breast 
conservation. In the context of labc and ibc, there 
is increasing evidence that her2-targeted strategies 
used in the adjuvant setting may be applicable in the 
neoadjuvant setting. Data from the two randomized 
controlled trials of trastuzumab versus no trastuzumab 
in operable breast cancer (MD Anderson Trial) or in 
labc and ibc (noah trial) showed that trastuzumab is 
associated with a significant increase in pcr. In the 
absence of data from randomized trials comparing 
neoadjuvant with adjuvant trastuzumab, the panel 
felt that initiating trastuzumab preoperatively and 
continuing it postoperatively for 1 year in total is rea-
sonable. In an ongoing phase iii trial in her2-positive 
breast cancer (Neo-Adjuvant Lapatinib and/or Tras-
tuzumab Treatment Optimisation), the total duration 
of her2-targeted therapy is also 1 year.
Whether trastuzumab should be given concur-
rently with chemotherapy or after chemotherapy 
remains an open question. Answers will be obtained 
with the analysis of the ncctg 9831 trial in which 
trastuzumab was given concurrently with paclitaxel 
in one arm and trastuzumab was given sequentially 
in another arm in the adjuvant setting.
The transfer to the neoadjuvant setting of 
regimens proven efficacious in the adjuvant setting 
is supported by a meta-analysis 1. Although the 
regimens used were mainly doxorubicin and cyclo-
phosphamide (ac), fac, and fe60c, it is reasonable 
to believe that other chemotherapy regimens would 
be as efficacious if given preoperatively compared 
with postoperatively. However, the optimal dura-
tion of chemotherapy is unknown. For example, the 
preliminary results of the nsabp 30 trial in operable 
breast cancer showed that 8 cycles of chemotherapy 
(ac followed by docetaxel) were superior to 4 cycles 
of doxorubicin and docetaxel or of docetaxel, doxo-
rubicin, and cyclophosphamide 45.
Although the efficacy results are quite convinc-
ing, the panel warned that a decision to give concur-
rent neoadjuvant anthracyclines with trastuzumab 
could not be made based on the neoadjuvant trials 
conducted to date. More studies and longer follow-up 
from the aforementioned trials, with particular atten-55
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tion to cardiac effects, are required to provide further 
insight into the cardiac safety of such combinations.
7.  CONCLUSIONS
Trastuzumab has become a standard of care in the 
adjuvant and metastatic settings for patients with 
her2-positive breast cancer. The evolving data in the 
neoadjuvant setting suggest that the addition of trastu-
zumab to neoadjuvant systemic therapy significantly 
increases pcr, breast conservation rates, and event-
free survival. A strategy of concurrent anthracyclines 
with trastuzumab appears promising, possibly further 
maximizing the efficacy of trastuzumab in high-risk 
patient populations. However, the cardiotoxicity 
risk (although relatively low so far) continues to be 
a concern. The present article provided panel sug-
gestions based on available data about the use of 
trastuzumab preoperatively. The suggestions set out 
here will continue to evolve as data and experience 
with trastuzumab and other her2-targeted agents in 
trials of neoadjuvant systemic therapy emerge.
8.  DATE OF PANEL SUGGESTIONS
Panel suggestions were completed in June 2009.
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